{
  "name": "Neuromuscular",
  "slug": "neuromuscular",
  "icon": "üí™",
  "color": "bg-emerald-100 text-emerald-800 border-emerald-200",
  "toc": [
    {
      "level": 1,
      "text": "Guillain-Barre Syndrome (GBS)",
      "id": "guillain-barre-syndrome-gbs"
    },
    {
      "level": 2,
      "text": "GBS ‚Äî Acute Workup & Management Protocol",
      "id": "gbs-acute-workup"
    },
    {
      "level": 3,
      "text": "Diagnostic Workup",
      "id": "gbs-diagnosis"
    },
    {
      "level": 3,
      "text": "Respiratory Monitoring ‚Äî \"20/30/40 Rule\"",
      "id": "gbs-respiratory-monitoring"
    },
    {
      "level": 3,
      "text": "Treatment Protocol",
      "id": "gbs-treatment-protocol"
    },
    {
      "level": 1,
      "text": "Neonatal Hypotonia Etiology and Exam",
      "id": "neonatal-hypotonia-etiology-and-exam"
    },
    {
      "level": 1,
      "text": "Spinal Muscular Atrophy (SMA)",
      "id": "spinal-muscular-atrophy-sma"
    },
    {
      "level": 1,
      "text": "Duchenne Muscular Dystrophy (DMD)",
      "id": "duchenne-muscular-dystrophy-dmd"
    }
  ],
  "html": "<div style=\"display:flex;align-items:center;gap:0.75rem;background:#ecfdf5;border-left:4px solid #059669;border-radius:0 10px 10px 0;padding:0.75rem 1rem;margin:0 0 1.5rem;\"><span style=\"font-size:1.25rem;\" aria-hidden=\"true\">üîó</span><div><a href=\"https://neuromuscular-db.vercel.app/\" target=\"_blank\" rel=\"noopener\" style=\"font-weight:600;color:#059669;text-decoration:none;font-size:0.95rem;\">Neuromuscular Disease Database ‚Üí</a><p style=\"margin:0.15rem 0 0;font-size:0.75rem;color:#6b7280;\">Comprehensive reference for neuromuscular conditions, diagnostics, and management</p></div></div><h1 id=\"guillain-barre-syndrome-gbs\">Guillain-Barre Syndrome (GBS)</h1><ul><li>Autoimmune demyelinating polyradiculopathy</li><li>Variants<ul><li>Axonal</li><li>Miller Fisher (ataxia, ophthalmoplegia, and areflexia)</li></ul></li><li>Presents with tingling, weakness, sensory ataxia</li><li>¬Ω will have antecedent viral illness. GI illness think-- campylobacter</li><li>¬Ω individuals will have bilateral facial weakness</li><li>Weakness progresses rapidly with nadir at 2 weeks for 50% of pts, 3 weeks for 80%, and rest by 4 weeks</li></ul><p><strong>DDX:</strong> tick paralysis, cord trauma/ischemia, transverse myelitis viral myositis, botulism, poliomyelitis, diphtheria, porphyria, myasthenia, hypophosphatemia and kalemia, intoxications, lyme, acute HIV</p><p><strong>Work Up: consider</strong></p><ul><li>CSF for elevated protein </li><li>Mycoplasma, CMV, C.Jejuni, GQ1B, GM1 ab, LP with WNV PCR</li><li>EMG, NCV ‚Äìchecking for axonal variant and to confirm; only used in the acute setting if a clinical diagnosis cannot be made<ul><li>Can consider obtaining 4-6 weeks after presentation to look for an axonal variant if recovery is slow</li></ul></li><li>IgA level to determine chance of allergy to IVIG</li><li>MRI brain and spine with and without contrast</li></ul><p><strong>Management</strong></p><ul><li>ICU telemetry, respiratory checks (NIFs) &gt; 4 x per day, intubate if vital capacity &lt; 20 ml/kg or use NIFs which are more sensitive. If NIF &lt;25-30 then intubate. </li><li>IVIG 2 gram/kilogram over 2 (some attendings do over 5 days)</li><li>DVT prophylaxis, PT and Rehab</li><li>Steroids not helpful, plasma exchange may be needed in severe cases</li><li>FACTS ABOUT SAFETY OF IVIG<ul><li>IVIG is pooled antibody from human donors. The risks are reduced from (1) screening plasma donors, (2) testing the presence of certain current virus infections and including virus inactivation, (3) removal steps in the manufacturing of most IVIG products. </li><li>In the literature there has never been a reported case of transmitted Hep B or HIV via IVIG. Only one case of Hep C transmission.  </li></ul></li></ul><p><strong>GBS Prognosis</strong></p><ul><li>Recovery begins within 2-4 weeks after progression stops</li><li>In mild cases, there may be a full recovery within a few weeks</li><li>In more severe cases or in cases with axonal injury, such as AMAN, recovery can take up to a year.</li></ul>\n<h2 id=\"gbs-acute-workup\">GBS ‚Äî Acute Workup &amp; Management Protocol</h2>\n\n<h3 id=\"gbs-diagnosis\">Diagnostic Workup</h3>\n<div class=\"protocol-box\">\n<p><strong>Lumbar Puncture:</strong></p>\n<ul>\n<li>Classic finding: <strong>albuminocytologic dissociation</strong> (elevated protein, normal WBC &lt; 10/¬µL)</li>\n<li>CSF protein may be <strong>normal in the first week</strong> ‚Äî sensitivity improves after day 7</li>\n<li>If WBC &gt; 50/¬µL ‚Üí reconsider diagnosis (think infectious, HIV, Lyme, CMV)</li>\n</ul>\n<p><strong>NCS/EMG:</strong></p>\n<ul>\n<li>May be <strong>normal in first 1-2 weeks</strong></li>\n<li>Optimal timing: <strong>2-3 weeks after symptom onset</strong></li>\n<li>Early findings: prolonged F-waves, prolonged distal latencies, absent H-reflexes</li>\n<li>Helps classify subtype: AIDP (demyelinating, most common) vs AMAN/AMSAN (axonal)</li>\n</ul>\n<p><strong>Additional labs:</strong> Anti-ganglioside antibodies (anti-GM1, anti-GD1a, anti-GQ1b for Miller Fisher variant), Lyme serology, HIV if risk factors</p>\n</div>\n\n<h3 id=\"gbs-respiratory-monitoring\">Respiratory Monitoring ‚Äî \"20/30/40 Rule\"</h3>\n<div class=\"red-flag-box\">\n<p><strong>Monitor FVC (forced vital capacity) every 4-6 hours in all GBS patients:</strong></p>\n<ul>\n<li><strong>FVC &lt; 20 mL/kg</strong> ‚Üí consider ICU transfer / intubation</li>\n<li><strong>NIF (MIP) &lt; -30 cmH‚ÇÇO</strong> ‚Üí respiratory muscles weakening</li>\n<li><strong>FVC declining &gt; 30%</strong> from baseline ‚Üí rapid progression, prepare for intubation</li>\n</ul>\n<p><strong>Other intubation indicators:</strong> inability to count to 20 in one breath, paradoxical abdominal breathing, oxygen desaturation, inability to lift head off bed</p>\n<p><strong>Do NOT rely on pulse oximetry alone</strong> ‚Äî desaturation is a LATE finding in neuromuscular respiratory failure.</p>\n</div>\n\n<h3 id=\"gbs-treatment-protocol\">Treatment Protocol</h3>\n<div class=\"protocol-box\">\n<p><strong>IVIG (first-line in pediatrics):</strong></p>\n<ul>\n<li><strong>Dose: 2 g/kg total</strong>, given over 2-5 days (e.g., 0.4 g/kg/day √ó 5 days)</li>\n<li>Check IgA level before first dose (IgA deficiency ‚Üí anaphylaxis risk)</li>\n<li>Monitor for adverse effects: headache, aseptic meningitis, renal dysfunction, thrombosis</li>\n</ul>\n<p><strong>Plasmapheresis (PLEX):</strong></p>\n<ul>\n<li>Alternative to IVIG ‚Äî equally effective in severe cases</li>\n<li>Typically 5 exchanges over 1-2 weeks</li>\n<li>Preferred if IVIG contraindicated or patient not improving</li>\n<li><strong>Do NOT give IVIG after PLEX</strong> (PLEX removes the IVIG)</li>\n</ul>\n<p><strong>Steroids are NOT effective in GBS</strong> (unlike CIDP)</p>\n<p><strong>Supportive:</strong> DVT prophylaxis, pain management (neuropathic pain common ‚Äî gabapentin), monitor for autonomic instability (BP swings, arrhythmia), early PT/OT</p>\n</div><h1 id=\"neonatal-hypotonia-etiology-and-exam\">Neonatal Hypotonia Etiology and Exam</h1><div class=\"table-wrap\"><table><tbody><tr><td><p><strong>Causes of Neonatal Hypotonia </strong></p></td><td></td></tr><tr><td><p><strong>Central (most common)</strong></p></td><td><p>HIE</p><p>Intracranial hemorrhage</p><p>Cerebral malformation</p><p>Chromosomal abnl 21, Prader Willi</p><p>Congenital infections (TORCHES)</p><p>Acquired infections</p><p>Peroxisomal disorders</p><p>Drug effects (benzodiazepines)</p></td></tr><tr><td><p><strong>Spinal Cord</strong></p></td><td><p>Birth trauma</p><p>Syringomyelia</p></td></tr><tr><td><p><strong>Anterior Horn Cell</strong></p></td><td><p>Spinal muscular atrophy</p></td></tr><tr><td><p><strong>Neuromuscular-junction</strong></p></td><td><p>Myasthenia gravis (transient or congenital)</p><p>Infantile botulism</p></td></tr><tr><td><p><strong>Muscle</strong></p></td><td><p>Muscular dystrophy (inc congenital myotonic dystrophy)</p><p>Congenital myopathies (eg. Central core disease)</p></td></tr><tr><td><p><strong>Peripheral</strong></p></td><td><p>Hereditary motor and sensory neuropathies</p></td></tr><tr><td><p><strong>Metabolic myopathies</strong></p></td><td><p>Acid maltase deficiency (Pompe disease)</p><p>Carnitine deficiency</p><p>Cytochrome-c-oxidase deficiency</p></td></tr></tbody></table></div><div class=\"table-wrap\"><table><tbody><tr><td><p><strong>Hypotonia PE</strong></p></td><td><p><strong>Strength</strong></p></td><td><p><strong>Reflexes</strong></p></td><td><p><strong>Other</strong></p></td></tr><tr><td><p><strong>Central</strong></p></td><td><p>Normal</p></td><td><p>Nl to inc</p></td><td><p>+/- seizures</p><p>+/-</p></td></tr><tr><td><p><strong>Anterior Horn cell</strong></p></td><td><p>Generalized weakness</p></td><td><p>Decreased to absent</p></td><td><p>+/- fasciculations</p><p>described as alert</p></td></tr><tr><td><p><strong>Nerve</strong></p></td><td><p>weakness, distal&gt;peripheral</p></td><td><p>Decreased to absent</p></td><td><p>+/- fasciculations</p></td></tr><tr><td><p><strong>NMJ</strong></p></td><td><p>Facial/bulbar weakness</p></td><td><p>decreased</p></td><td><p>No fasciculations</p></td></tr><tr><td><p><strong>Muscle</strong></p></td><td><p>Weakness prox&gt;distal</p></td><td><p>decreased</p></td><td></td></tr></tbody></table></div><h1 id=\"spinal-muscular-atrophy-sma\">Spinal Muscular Atrophy (SMA)</h1><p>SMA is characterized by degeneration of the anterior horn cells in the spinal cord and motor nuclei in the lower brainstem, which results in progressive muscle weakness and atrophy. The diagnosis of SMA should be suspected for any infant with unexplained weakness or hypotonia.</p><p>Molecular genetic testing with targeted mutation analysis can confirm the diagnosis of SMA by detection of homozygous deletions of exons 7 of the SMN1 gene. </p><div class=\"table-wrap\"><table><tbody><tr><td><p><strong>Type</strong></p></td><td><p><strong>Age of onset</strong></p></td><td><p><strong>Requires respiratory support at birth</strong></p></td><td><p><strong>Able to sit</strong></p></td><td><p><strong>Able to stand</strong></p></td><td><p><strong>Able to walk</strong></p></td><td><p><strong>Life expectancy</strong></p></td><td><p><strong>Predicted <em>SMN2</em> copy number</strong></p></td></tr><tr><td><p>0</p></td><td><p>Prenatal</p></td><td><p>Yes</p></td><td><p>No</p></td><td><p>No</p></td><td><p>No</p></td><td><p>&lt;6 months</p></td><td><p>1</p></td></tr><tr><td><p>1</p></td><td><p>&lt;6 months</p></td><td><p>No</p></td><td><p>No</p></td><td><p>No</p></td><td><p>No</p></td><td><p>&lt;2 years</p></td><td><p>2</p></td></tr><tr><td><p>2</p></td><td><p>6 to 18 months</p></td><td><p>No</p></td><td><p>Yes</p></td><td><p>No</p></td><td><p>No</p></td><td><p>10 to 40 years</p></td><td><p>3</p></td></tr><tr><td><p>3</p></td><td><p>&gt;18 months</p></td><td><p>No</p></td><td><p>Yes</p></td><td><p>Yes</p></td><td><p>Assisted</p></td><td><p>Adult</p></td><td><p>3 to 4</p></td></tr><tr><td><p>4</p></td><td><p>&gt;5 years</p></td><td><p>No</p></td><td><p>Yes</p></td><td><p>Yes</p></td><td><p>Yes</p></td><td><p>Adult</p></td><td><p>&gt;4</p></td></tr></tbody></table></div><p><strong>Spinraza (nusinersen)</strong>: antisense oligonucleotide (ASO) that modifies splicing of the <em>SMN2 </em>gene to increase production of normal, full-length survival motor neuron protein. Stops progression and may improve some function. </p><ul><li>Intrathecal injection done via IR or through Procedure Center</li><li>Standard Dose (not weight based): Nusinersen (2.4 mg/mL) intrathecal injection, 12 mg injected over 1-3 minutes.</li><li>Pre-labs (done per FDA due to adverse effects seen in OTHER ASOs, not observed in Spinraza yet): PT/PTT, Plt, Urine protein</li><li>Common side effects (mostly just related to LP, not the drug itself):<ul><li>Post-LP headache: Treat with fluids, caffeine, prone. </li><li>Cramps: Treat with OTC analgesics, warm compress, rest</li><li>Fever: May need ED eval depending on other symptoms and severity of those symptoms.</li><li>Back pain: OTC analgesics, rest</li></ul></li></ul><ul><li>Delivery schedule:</li></ul><p><img alt=\"\" src=\"/images/neuromuscular/img-1.png\" class=\"max-w-full rounded-lg my-4 mx-auto block\"></p><p><strong>Zolgensma (onasemnogene abeparvovec-xioi): </strong>gene transfer therapy that uses adeno-associated viral (AAV) vector to provide a functional replacement of <em>SMN1 </em>gene. This allows the patient to produce SMN protein which prevents ongoing neuronal cell death. Given as one time IV dose for SMA type 1 patients &lt; 2 years of age who possess two mutated copies of <em>SMN1. </em></p><ul><li>Common Side Effects:<ul><li>Thrombocytopenia</li><li>Elevated troponin</li><li>Elevated liver enzymes and acute liver injury</li></ul></li></ul><ul><li>Side effects mitigated by prednisone course starting prior to infusion and 30 days after.</li><li>Patients will be admitted to Yellow Team as ‚Äòbedded outpatients‚Äô (typically they do not stay overnight unless there are complications). The neurology team is given a ‚Äòheads-up‚Äô and only needs to perform a consult IF there are problems. Yellow Team to ‚Äúclear‚Äù patient for infusion (ensure no fevers/infectious concerns or change from baseline respiratory status). Individuals involved: someone from Complex Drugs Team, one of the neurology or rehab providers from muscle clinic. </li><li>Contact: Taylor Schwab, Neurology Complex Drugs RN Coordinator at 7-0836 (PCD) when patient arrives or with any questions or concerns on day of infusion. </li></ul><p>&nbsp;References</p><ul><li>Al-Zaidy, SA, Mendell, JR.&nbsp;From clinical trials to clinical practice: practical considerations for gene replacement therapy in SMA type 1. Pediatr Neurol.&nbsp;2019;100:3-11. doi:<a href=\"https://doi.org/10.1016/j.pediatrneurol.2019.06.007\">10.1016/j.pediatrneurol.2019.06.007</a></li></ul><ul><li>Stevens D, Claborn MK, Gildon BL, Kessler TL, Walker C. Onasemnogene Abeparvovec-xioi: Gene Therapy for Spinal Muscular Atrophy.&nbsp;<em>Ann Pharmacother</em>. 2020;54(10):1001-1009. doi:10.1177/1060028020914274</li></ul><h1 id=\"duchenne-muscular-dystrophy-dmd\">Duchenne Muscular Dystrophy (DMD)</h1><p>DMD is an X-linked recessive disorder caused by mutations of the dystrophin gene that result in absent or insufficient functional dystrophin protein. Results in progressive muscular weakness, loss of ambulation, respiratory impairment, and cardiomyopathy. </p><p><img src=\"/images/neuromuscular/img-2.jpg\" alt=\"\" class=\"max-w-full rounded-lg my-4 mx-auto block\"></p><p><strong>Neuromuscular Management of DMD:</strong></p><p><img alt=\"\" src=\"/images/neuromuscular/img-3.jpg\" class=\"max-w-full rounded-lg my-4 mx-auto block\"></p><p><strong>Common comorbid conditions:</strong></p><ul><li><strong>GI</strong>: GERD, constipation, swallowing dysfunction. Need osmotic laxatives, retrograde enemas. Ranitidine or PPIs.</li><li><strong>Nutrition</strong>: obesity usually while on steroids. Underweight due to poor intake. </li><li><strong>Pulmonary</strong>: Complications include respiratory muscle fatigue, mucus plugging, atelectasis, pneumonia, and respiratory failure. Need regular spirometry testing to assess function.</li><li><strong>Cardiology</strong>: cardiomyopathy, high blood pressure.  Need to assess cardiac function annually; may need beta-blockers, ACE inhibitors.</li><li><strong>Endocrinology</strong>: impaired linear growth and puberty exacerbated by corticosteroids. Osteoporosis, vitamin D deficiency and adrenal insufficiency if on corticosteroids.  May need IV Bisphosphonate if has osteoporosis. Could have adrenal crisis- ER IM hydrocortisone. Hypogonadism and may need testosterone.</li><li><strong>Psychiatry/neuropsychology</strong>: depression, cognitive/learning impairment. </li><li><strong>MSK</strong>: scoliosis, contractures. </li></ul><p><strong>Female carriers:</strong> family members of an individual with DMD should receive genetic counselling to establish who is at risk of being a carrier. Carrier testing is recommended for female relatives of a boy or man who has been genetically confirmed to have DMD. There is a carrier clinic available for families with known diagnosis of DMD. </p><p><strong>Targeted Therapies for DMD :</strong></p><ul><li>Exon Skipping therapies: antisense oligonucleotides. Used for the treatment of DMD patients that have a confirmed mutation in the specific exon skipping region.<ul><li>EXONDYS 51 (eteplirsen): exon 51 skipping. FDA approval September 19, 2016.</li><li>VYONDYS 53 (Golodirsen): exon 53 skipping. FDA approved on December 12, 2019.</li><li>VILTEPSO (viltolarsen): exon 53 skipping. FDA approved on August 12, 2020.</li><li>AMONDYS 45 (casimersen): exon 45 skipping. FDA approved February 25, 2021.</li></ul></li></ul><ul><li>Administration is weekly for life or until patient/families wishes to stop or insurance approval is no longer obtained. First infusions typically given via the infusion center to monitor for adverse reactions, including hypersensitivity reactions, upper respiratory tract infection, injection site reaction, cough, pyrexia, contusion, arthralgia, diarrhea, vomiting, abdominal pain, ejection fraction decreased, urticaria. If patient tolerates first several infusions in hospital, subsequent infusions can be administered by home health RN via port-a-cath. Routine labs are obtained before and during treatment to monitor for kidney toxicity. </li><li>Treatment on the close horizon: Microdystrophin (gene therapy) </li></ul>",
  "imageCount": 3,
  "chunkCount": 4
}